JP2023514280A - ｓｅｔｄ２阻害剤、および関連する方法と使用（併用療法を含む） - Google Patents

ｓｅｔｄ２阻害剤、および関連する方法と使用（併用療法を含む） Download PDF

Info

Publication number
JP2023514280A
JP2023514280A JP2022549325A JP2022549325A JP2023514280A JP 2023514280 A JP2023514280 A JP 2023514280A JP 2022549325 A JP2022549325 A JP 2022549325A JP 2022549325 A JP2022549325 A JP 2022549325A JP 2023514280 A JP2023514280 A JP 2023514280A
Authority
JP
Japan
Prior art keywords
alkyl
group
cycloalkyl
hydroxy
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514280A5 (https=
JPWO2021168313A5 (https=
Inventor
アレハンドラ ライモンディ マリア
アン トットマン ジェニファー
モトワニ ヴィニー
ルイーズ コスモポウロス キャサリン
ランプ ジョン
Original Assignee
エピザイム インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム インコーポレイテッド filed Critical エピザイム インコーポレイテッド
Publication of JP2023514280A publication Critical patent/JP2023514280A/ja
Publication of JP2023514280A5 publication Critical patent/JP2023514280A5/ja
Publication of JPWO2021168313A5 publication Critical patent/JPWO2021168313A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022549325A 2020-02-19 2021-02-19 ｓｅｔｄ２阻害剤、および関連する方法と使用（併用療法を含む） Pending JP2023514280A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062978692P 2020-02-19 2020-02-19
US62/978,692 2020-02-19
PCT/US2021/018863 WO2021168313A1 (en) 2020-02-19 2021-02-19 Setd2 inhibitors and related methods and uses, including combination therapies

Publications (3)

Publication Number Publication Date
JP2023514280A true JP2023514280A (ja) 2023-04-05
JP2023514280A5 JP2023514280A5 (https=) 2024-02-27
JPWO2021168313A5 JPWO2021168313A5 (https=) 2024-02-27

Family

ID=77391740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549325A Pending JP2023514280A (ja) 2020-02-19 2021-02-19 ｓｅｔｄ２阻害剤、および関連する方法と使用（併用療法を含む）

Country Status (11)

Country Link
US (1) US20230133671A1 (https=)
EP (1) EP4107157A4 (https=)
JP (1) JP2023514280A (https=)
KR (1) KR20220143116A (https=)
CN (2) CN121695288A (https=)
AU (1) AU2021224855A1 (https=)
BR (1) BR112022016573A2 (https=)
CA (1) CA3168069A1 (https=)
IL (1) IL295654A (https=)
MX (1) MX2022010171A (https=)
WO (1) WO2021168313A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530844A (ja) 2017-08-14 2020-10-29 エピザイム，インコーポレイティド Ｓｅｔｄ２を阻害することにより癌を処置する方法
CN111093660A (zh) * 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
CN112585119A (zh) 2018-08-14 2021-03-30 Epizyme股份有限公司 经取代的吲哚及其使用方法
US20240299352A1 (en) * 2021-06-09 2024-09-12 Epizyme, Inc. Combination therapies with setd2 inhibitors
JP2024539726A (ja) * 2021-11-01 2024-10-29 エピザイム，インコーポレイティド Ｎ－（（１ｒ，３ｓ）－３－（４－アセチルピペラジン－１－イル）シクロヘキシル）－４－フルオロ－７－メチル－１ｈ－インドール－２－カルボキサミドの結晶形態

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509682A (ja) * 2014-04-04 2017-04-06 イオメット ファーマ リミテッド 医療で使用されるインドール誘導体
JP2021536428A (ja) * 2018-08-14 2021-12-27 エピザイム，インコーポレイティド 置換インドール及びその使用方法
JP2022511443A (ja) * 2018-11-30 2022-01-31 エピザイム，インコーポレイティド Ｓｅｔｄ２を阻害することにより、ｗｈｓｃ１を過剰発現する癌を処置する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595766A (en) * 1984-10-26 1986-06-17 Ciba-Geigy Corporation Process for the preparation of an indoline carboxylic acid
US20100035862A1 (en) * 2008-06-25 2010-02-11 Abbott Laboratories Novel aza-cyclic indole-2-carboxamides and methods of use thereof
WO2016040505A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509682A (ja) * 2014-04-04 2017-04-06 イオメット ファーマ リミテッド 医療で使用されるインドール誘導体
JP2021536428A (ja) * 2018-08-14 2021-12-27 エピザイム，インコーポレイティド 置換インドール及びその使用方法
JP2022511443A (ja) * 2018-11-30 2022-01-31 エピザイム，インコーポレイティド Ｓｅｔｄ２を阻害することにより、ｗｈｓｃ１を過剰発現する癌を処置する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, JPN5023005960, 2010, pages 4620 - 4623, ISSN: 0005577391 *
SARCOMA, vol. 2016, JPN5023005962, 29 September 2016 (2016-09-29), pages 7461783 - 1, ISSN: 0005577392 *

Also Published As

Publication number Publication date
EP4107157A4 (en) 2024-03-13
MX2022010171A (es) 2022-12-06
BR112022016573A2 (pt) 2022-11-08
CA3168069A1 (en) 2021-08-26
WO2021168313A1 (en) 2021-08-26
KR20220143116A (ko) 2022-10-24
EP4107157A1 (en) 2022-12-28
CN115380033B (zh) 2026-01-09
AU2021224855A1 (en) 2022-09-08
CN121695288A (zh) 2026-03-20
CN115380033A (zh) 2022-11-22
US20230133671A1 (en) 2023-05-04
IL295654A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
JP2023514280A (ja) ｓｅｔｄ２阻害剤、および関連する方法と使用（併用療法を含む）
JP7627209B2 (ja) 置換インドール及びその使用方法
KR102559719B1 (ko) 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
CA3215949A1 (en) Oxazepine compounds and uses thereof in the treatment of cancer
CN107531683B (zh) Usp7抑制剂化合物及使用方法
CN109790166A (zh) 咪唑并吡啶化合物用于治疗癌症
CA2652109A1 (en) Compositions and methods for modulating gated ion channels
JP2024522184A (ja) Ｓｅｔｄ２阻害剤との併用療法
WO2019183145A1 (en) Compounds and methods for ido and tdo modulation, and indications therefor
ES2358445T3 (es) Derivados de azabiciclo (3.1.0) hexano útiles como moduladores de los receptores d3 de dopamina.
CN112759588B (zh) 苯并五元杂环胺类衍生物及其用途
TW201902892A (zh) 化合物
JPWO2021168313A5 (https=)
HK40084091A (en) Setd2 inhibitors and related methods and uses, including combination therapies
WO2025184565A1 (en) Targeted protein modification
KR20240110971A (ko) 화합물
HK40057478B (zh) Hpk1抑制剂及其使用方法
EA045216B1 (ru) Производные 2-изоиндол-1,3,4-оксадиазола, применимые в качестве ингибиторов hdac6
HK40062143B (zh) 作为eed抑制剂的咪唑幷嘧啶和其用途
HK1248684B (en) Usp7 inhibitor compounds and methods of use
HK40019825A (en) Therapeutic compounds and compositions, and methods of use thereof

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20231107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260120